Nygaard Ulrikka, Larsen Jacob, Kristensen Tim D, Wesenberg Finn, Jonsson Olafur G, Carlsen Niels T, Forestier Erik, Kirchhoff Maria, Larsen Jørgen K, Schmiegelow Kjeld, Christensen Ib J
Department of Pediatrics, The University Hospital of Copenhagen, Rigshospitalet, Copenhagen, Denmark.
J Pediatr Hematol Oncol. 2006 Mar;28(3):134-40. doi: 10.1097/01.mph.0000210064.80828.3e.
High hyperdiploid acute lymphoblastic leukemia in children is related to a good outcome. Because these patients may be stratified to a low-intensity treatment, we have investigated the sensitivity of flow cytometry (FCM), G-band karyotyping (GBK), and high-resolution comparative genomic hybridization (HR-CGH) in detecting high hyperdiploid leukemic clones. Twenty-six girls and 34 boys with acute lymphoblastic leukemia diagnosed in 1998 to 1999 were analyzed by FCM, GBK, and HR-CGH. The correlations between DNA indices obtained by FCM, GBK, and HR-CGH were significant (rs=0.61 to 0.77; P<0.001 for all comparisons). However, in 4 of 18 patients, high hyperdiploidy was overlooked by GBK or HR-CGH, and even when FCM was applied, 2 of 18 patients with high hyperdiploidy by GBK and/or HR-CGH were classified as nonhigh hyperdiploid. If high hyperdiploid subclones were included, FCM could detect all high hyperdiploid patients found by either GBK or HR-CGH, but would then in addition classify 15% to 20% of the remaining patients as high hyperdiploid. Thus, both GBK and HR-CGH overlook patients with high hyperdiploidy, and FCM only detects all high hyperdiploid patients if small high hyperdiploid clones are included. In addition, FCM detects patients with high hyperdiploid subclones, not detected by either GBK or HR-CGH, and the challenge remains to determine the prognosis of patients with such high hyperdiploid subclones.
儿童高超二倍体急性淋巴细胞白血病与良好预后相关。由于这些患者可能被分层至低强度治疗,我们研究了流式细胞术(FCM)、G带核型分析(GBK)和高分辨率比较基因组杂交(HR-CGH)检测高超二倍体白血病克隆的敏感性。对1998年至1999年诊断为急性淋巴细胞白血病的26名女孩和34名男孩进行了FCM、GBK和HR-CGH分析。FCM、GBK和HR-CGH获得的DNA指数之间的相关性显著(rs = 0.61至0.77;所有比较的P < 0.001)。然而,在18例患者中有4例,GBK或HR-CGH遗漏了高超二倍体,甚至在应用FCM时,GBK和/或HR-CGH诊断为高超二倍体的18例患者中有2例被归类为非高超二倍体。如果纳入高超二倍体亚克隆,FCM可以检测到GBK或HR-CGH发现的所有高超二倍体患者,但此外还会将其余患者的15%至20%归类为高超二倍体。因此,GBK和HR-CGH都会遗漏高超二倍体患者,只有纳入小的高超二倍体克隆时FCM才能检测到所有高超二倍体患者。此外,FCM能检测到GBK和HR-CGH均未检测到的高超二倍体亚克隆患者,而确定此类高超二倍体亚克隆患者的预后仍然是一项挑战。